Avid Bioservices Inc (CDMO)

[vinmantoo]

I would rather ask why Dr. Jedd Wolchok at MSK is placing PS Targeting in play with other IO drugs in combo Why would those BP's that back other IO drugs want MSK to combine their IO drugs with PS Targeting ?

I gave a series of reasons to help explain why Bavi keeps failing in human clinical trials. You avoided addressing my points. Instead you repost nebulous explorations which may include Bavi in some small subset as part of a larger approach to examine combinatorial immunomodulation. By PS targeting, I assume you mean tumor cell receptors like Tims, which associate with PS near their cytoplasmic proximal domains. These are far superior targets as they will be much fewer in number.

That is the only question one should be looking at and then open up and realize that 26 top cancer hospitals ( and their network hospitals which places PS Targeting in 26+ institutions all part of NCCN --- do not accept any drug into their network

As far as what others are testing, why wouldn't they want to explore all aspects when it doesn't cost them money? They are using known effective immunomodulators as the base, not Bavi, then adding various additional factors which they hope will provide synergistic improvement in efficacy, one of a large number of which is Bavi. You are acting as if Bavi is the main driver and component of such studies, and what they consider their best hope. It is very clearly nothing of the sort.

Peregrine already proved that they no longer need to pay big money for Phase III's because all know exactly what happened in Fargo and with a raw deal control arm in Sunrise

Right, you keep believing that if it gets you through the night. Raw deal in the control arm??? Yes, the nerve of patients in the control arm screwing PPHM by living too long, and the nerve of patients in the control arm screwing PPHM by NOT living longer than those in the control arm.

No other drug or small biotech can continue to be as stubborn as Peregrine in demanding what they want and to maintain as much IP leverage as possible

No, it couldn't be that other companies aren't interested in Bavi, especially after so many failures in clinical trials. It has to be the astute, excellent PPHM management who are protecting the interests of PPHM shareholders by rejecting the plethora of offers made by Big, Medium and small Pharma for Bavi rights.

Maybe that is why Dr. Rolf Brekken believes PS Targeting will be approved....

not IF...just WHEN

Pretty arrogant to make that statement after all the Bavi failures. Right, he is an objective observer with no ties to PPHM so his word should be taken as fact.